The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study
Open accessAbstract
BACKGROUND: The metabolic basis of Alzheimer disease (AD) is poorly understood, and the relationships between systemic abnormalities in metabolism and AD pathogenesis are unclear. Understanding how global perturbations in metabolism are related to severity of AD neuropathology and the eventual expression of AD symptoms in at-risk individuals is critical to developing effective disease-modifying treatments. In this study, we undertook parallel metabolomics analyses in both the brain and blood to identify systemic correlates of neuropathology and their associations with prodromal and preclinical measures of AD progression. METHODS AND FINDINGS: Quantitative and targeted metabolomics (Biocrates AbsoluteIDQ [identification and quantification] p180) assays were performed on brain tissue samples from the autopsy cohort of the Baltimore Longitudinal Study of Aging (BLSA) (N = 44, mean age = 81.33, % female = 36.36) from AD (N = 15), control (CN; N = 14), and "asymptomatic Alzheimer's disease" (ASYMAD, i.e., individuals with significant AD pathology but no cognitive impairment during life; N = 15) participants. Using machine-learning methods, we identified a panel of 26 metabolites from two main classes-sphingolipids and glycerophospholipids-that discriminated AD and CN samples with accuracy, sensitivity, and specificity of 83.33%, 86.67%, and 80%, respectively. We then assayed these 26 metabolites in serum samples from two well-characterized longitudinal cohorts representing prodromal (Alzheimer's Disease Neuroimaging Initiative [ADNI], N = 767, mean age = 75.19, % female = 42.63) and preclinical (BLSA) (N = 207, mean age = 78.68, % female = 42.63) AD, in which we tested their associations with magnetic resonance imaging (MRI) measures of AD-related brain atrophy, cerebrospinal fluid (CSF) biomarkers of AD pathology, risk of conversion to incident AD, and trajectories of cognitive performance. We developed an integrated blood and brain endophenotype score that summarized the relative importance of each metabolite to severity of AD pathology and disease progression (Endophenotype Association Score in Early Alzheimer's Disease [EASE-AD]). Finally, we mapped the main metabolite classes emerging from our analyses to key biological pathways implicated in AD pathogenesis. We found that distinct sphingolipid species including sphingomyelin (SM) with acyl residue sums C16:0, C18:1, and C16:1 (SM C16:0, SM C18:1, SM C16:1) and hydroxysphingomyelin with acyl residue sum C14:1 (SM (OH) C14:1) were consistently associated with severity of AD pathology at autopsy and AD progression across prodromal and preclinical stages. Higher log-transformed blood concentrations of all four sphingolipids in cognitively normal individuals were significantly associated with increased risk of future conversion to incident AD: SM C16:0 (hazard ratio [HR] = 4.430, 95% confidence interval [CI] = 1.703-11.520, p = 0.002), SM C16:1 (HR = 3.455, 95% CI = 1.516-7.873, p = 0.003), SM (OH) C14:1 (HR = 3.539, 95% CI = 1.373-9.122, p = 0.009), and SM C18:1 (HR = 2.255, 95% CI = 1.047-4.855, p = 0.038). The sphingolipid species identified map to several biologically relevant pathways implicated in AD, including tau phosphorylation, amyloid-β (Aβ) metabolism, calcium homeostasis, acetylcholine biosynthesis, and apoptosis. Our study has limitations: the relatively small number of brain tissue samples may have limited our power to detect significant associations, control for heterogeneity between groups, and replicate our findings in independent, autopsy-derived brain samples. CONCLUSIONS: We present a novel framework to identify biologically relevant brain and blood metabolites associated with disease pathology and progression during the prodromal and preclinical stages of AD. Our results show that perturbations in sphingolipid metabolism are consistently associated with endophenotypes across preclinical and prodromal AD, as well as with AD pathology at autopsy. Sphingolipids may be biologically relevant biomarkers for the early detection of AD, and correcting perturbations in sphingolipid metabolism may be a plausible and novel therapeutic strategy in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cortes, C., & Vapnik, V. (1995) · Machine Learning · doi:10.1007/bf00994018 · Cited by 59,421
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Classification and Regression Trees.
Gordon, A. D., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984) · Biometrics · doi:10.2307/2530946 · Cited by 23,522
Classification and Regression Trees.
Ryzin, J. V., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1986) · Journal of the American Statistical Association · doi:10.2307/2288003 · Cited by 20,825
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Classification And Regression Trees
Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (2017) · doi:10.1201/9781315139470 · Cited by 11,417
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Principles of bioactive lipid signalling: lessons from sphingolipids
Hannun, Y. A., & Obeid, L. M. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2329 · Cited by 3,333
Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)
Spitzer, R. L., & Williams, J. (1987) · Cited by 1,823
The Alzheimer's Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.008 · Cited by 1,525
The Clinical Diagnosis of Alzheimer's Disease
Wade, J. P. H., Mirsen, T. R., Hachinski, V. C., Fisman, M., Lau, C., & Merskey, H. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520130016010 · Cited by 1,374
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid
Nguyen, L. N., Ma, D., Shui, G., Wong, P., Cazenave-Gassiot, A., Zhang, X., Wenk, M. R., Goh, E. L. K., & Silver, D. L. (2014) · Nature · doi:10.1038/nature13241 · Cited by 1,048
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Normal Human Aging: The Baltimore Longitudinal Study on Aging
Shock, N. W., Greulich, R. C., Costa, P. T., Andres, R., Lakatta, E. G., Arenberg, D., & Tobin, J. D. (1984) · University Libraries (University of Maryland) · doi:10.13016/sclw-iccq · Cited by 750
Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer Disease
Chan, R. B., Oliveira, T. G., Cortes, E. P., Honig, L. S., Duff, K. E., Small, S. A., Wenk, M. R., Shui, G., & Di Paolo, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274142 · Cited by 630
Deregulation of sphingolipid metabolism in Alzheimer’s disease
He, X., Huang, Y., Li, B., Gong, C.-X., & Schuchman, E. H. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.010 · Cited by 516
Janssen, C. I. F., & Kiliaan, A. J. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.10.002 · Cited by 514
Interaction of membrane/lipid rafts with the cytoskeleton: Impact on signaling and function
Head, B. P., Patel, H. H., & Insel, P. A. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.07.018 · Cited by 511
Normal Human Aging: The Baltimore Longitudinal Study of Aging
(1985) · Journal of Gerontology · doi:10.1093/geronj/40.6.767 · Cited by 474
Age-specific incidence rates of Alzheimer’s disease: The Baltimore Longitudinal Study of Aging
Kawas, C., Gray, S., Brookmeyer, R., Fozard, J., & Zonderman, A. (2000) · Neurology · doi:10.1212/wnl.54.11.2072 · Cited by 472
Metabolic network failures in Alzheimer's disease: A biochemical road map
Toledo, J. B., Arnold, M., Kastenmüller, G., Chang, R., Baillie, R. A., Han, X., Thambisetty, M., Tenenbaum, J. D., Suhre, K., Thompson, J. W., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.020 · Cited by 468
Self-citationHan, X., Rozen, S., Boyle, S. H., Hellegers, C., Cheng, H., Burke, J. R., Welsh-Bohmer, K. A., Doraiswamy, P. M., & Kaddurah-Daouk, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021643 · Cited by 429
Self-citationEvidence of altered phosphatidylcholine metabolism in Alzheimer's disease
Whiley, L., Sen, A., Heaton, J., Proitsi, P., García-Gómez, D., Leung, R., Smith, N., Thambisetty, M., Kloszewska, I., Mecocci, P., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.001 · Cited by 340
Self-citationDavatzikos, C., Xu, F., An, Y., Fan, Y., & Resnick, S. M. (2009) · Brain · doi:10.1093/brain/awp091 · Cited by 315
Self-citationSnowden, S. G., Ebshiana, A. A., Hye, A., An, Y., Pletnikova, O., O’Brien, R., Troncoso, J., Legido-Quigley, C., & Thambisetty, M. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002266 · Cited by 309
Self-citationThe Baltimore Longitudinal Study of Aging (BLSA): A 50-Year-Long Journey and Plans for the Future
Ferrucci, L. (2008) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/63.12.1416 · Cited by 290
Metabolome in progression to Alzheimer's disease
Orešič, M., Hyötyläinen, T., Herukka, S.-K., Sysi-Aho, M., Mattila, I., Seppänan-Laakso, T., Julkunen, V, Gopalacharyulu, P. V., Hallikainen, M., Koikkalainen, J., et al. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.55 · Cited by 277
Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis
Haughey, N. J., Bandaru, V. V. R., Bae, M., & Mattson, M. P. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.003 · Cited by 273
Direct and Potent Regulation of γ-Secretase by Its Lipid Microenvironment
Osenkowski, P., Ye, W., Wang, R., Wolfe, M. S., & Selkoe, D. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801925200 · Cited by 268
A comparative study of different machine learning methods on microarray gene expression data
Pirooznia, M., Yang, J. Y., Yang, M. Q., & Deng, Y. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-s1-s13 · Cited by 259
Jazvinšćak Jembrek, M., Hof, P. R., & Šimić, G. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/346783 · Cited by 244
Targeted Metabolomics Identifies Reliable and Stable Metabolites in Human Serum and Plasma Samples
Breier, M., Wahl, S., Prehn, C., Fugmann, M., Ferrari, U., Weise, M., Banning, F., Seissler, J., Grallert, H., Adamski, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089728 · Cited by 240
Protein-Mediated Fatty Acid Uptake: Novel Insights from In Vivo Models
Doege, H., & Stahl, A. (2006) · Physiology · doi:10.1152/physiol.00014.2006 · Cited by 222
Effect of infarcts on dementia in the Baltimore longitudinal study of aging
Troncoso, J. C., Zonderman, A. B., Resnick, S. M., Crain, B., Pletnikova, O., & O'Brien, R. J. (2008) · Annals of Neurology · doi:10.1002/ana.21413 · Cited by 219
Self-citationSoOderberg, M., Edlund, C., Alafuzoff, I., Kristensson, K., & Dallner, G. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10994.x · Cited by 209
Recent advances in the application of metabolomics to Alzheimer's Disease
Trushina, E., & Mielke, M. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.014 · Cited by 196
Serum sphingomyelins and ceramides are early predictors of memory impairment
Mielke, M. M., Bandaru, V. V. R., Haughey, N. J., Rabins, P. V., Lyketsos, C. G., & Carlson, M. C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.011 · Cited by 186
Blood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible
Thambisetty, M., & Lovestone, S. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.84 · Cited by 182
Self-citationFabelo, N., Martín, V., Marín, R., Moreno, D., Ferrer, I., & Díaz, M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.005 · Cited by 163
Casanova, R., Varma, S., Simpson, B., Kim, M., An, Y., Saldana, S., Riveros, C., Moscato, P., Griswold, M., Sonntag, D., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.12.008 · Cited by 162
Self-citationStoica, B. A., Movsesyan, V. A., Lea IV, P. M., & Faden, A. I. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(02)00028-3 · Cited by 160
Sphingolipid metabolism in neural cells
van Echten‐Deckert, G., & Herget, T. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.06.009 · Cited by 148
Neuropathologic Studies of the Baltimore Longitudinal Study of Aging (BLSA)
O'Brien, R. J., Resnick, S. M., Zonderman, A. B., Ferrucci, L., Crain, B. J., Pletnikova, O., Rudow, G., Iacono, D., Riudavets, M. A., Driscoll, I., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1179 · Cited by 137
Self-citationAsle‐Rousta, M., Kolahdooz, Z., Oryan, S., Ahmadiani, A., & Dargahi, L. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-9979-6 · Cited by 136
Hustad, S., Eussen, S. J. P. M., Midttun, Ø., Ulvik, A., van de Kant, P. M., Mørkrid, L., Gislefoss, R. E., & Ueland, P. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.174490 · Cited by 118
Effect of a clinical stroke on the risk of dementia in a prospective cohort
Gamaldo, A. A., Moghekar, A., Kilada, S., Resnick, S. M., Zonderman, A. B., & O’Brien, R. (2006) · Neurology · doi:10.1212/01.wnl.0000240285.89067.3f · Cited by 99
Self-citationIacono, D., Resnick, S. M., O’Brien, R., Zonderman, A. B., An, Y., Pletnikova, O., Rudow, G., Crain, B., & Troncoso, J. C. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000052 · Cited by 73
Self-citationBlood metabolite markers of cognitive performance and brain function in aging
Simpson, B. N., Kim, M. G., Chuang, Y., Beason‐Held, L. L., Kitner‐Triolo, M. H., Kraut, M. A., Lirette, S. T., Windham, B. G., Griswold, M. E., Legido‐Quigley, C., et al. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15611678 · Cited by 65
Self-citationBarba, I., Fernández-Montesinos, R., García‐Dorado, D., & Pozo, D. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00385.x · Cited by 63
Blood-Brain Barrier: A Dual Life of MFSD2A?
Zhao, Z., & Zlokovic, B. V. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.012 · Cited by 59
Norman, E. D., Cutler, R. G., Flannery, R. J., Wang, Y., & Mattson, M. P. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06779.x · Cited by 52
Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI
Toledo, J. B., Da, X., Bhatt, P., Wolk, D. A., Arnold, S. E., Shaw, L. M. J., Trojanowski, J. Q., Davatzikos, C. A., & Initiative, A. D. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055531 · Cited by 51
Self-citationPélerin, H., Jouin, M., Lallemand, M.-S., Alessandri, J., Cunnane, S. C., Goustard, B., & Guesnet, P. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.07.004 · Cited by 44
Li, D., Misialek, J. R., Boerwinkle, E., Gottesman, R. F., Sharrett, A. R., Mosley, T. H., Coresh, J., Wruck, L. M., Knopman, D. S., & Alonso, Á. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.09.003 · Cited by 44
Inoue, K., Tsuchiya, H., Takayama, T., Akatsu, H., Hashizume, Y., Yamamoto, T., Matsukawa, N., & Toyo’oka, T. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.10.022 · Cited by 36
Kim, E., Jung, Y., Kim, H., Kim, J.-S., Park, M., Jeong, J., Lee, S. K., Yoon, H., Hwang, G., & Namkoong, K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132165 · Cited by 31
Kolahdooz, Z., Nasoohi, S., Asle‐Rousta, M., Ahmadiani, A., & Dargahi, L. (2015) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2015.19 · Cited by 17
Cited by
Applications of multi‐omics analysis in human diseases
Chen, C., Wang, J., Pan, D., Wang, X., Xu, Y., Yan, J., Wang, L., Yang, X., Yang, M., & Liu, G. (2023) · MedComm · doi:10.1002/mco2.315 · Cited by 545
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
Brain lipidomics: From functional landscape to clinical significance
Yoon, J. H., Seo, Y., Jo, Y. S., Lee, S., Cho, E., Cazenave-Gassiot, A., Shin, Y.-S., Moon, M. H., An, H. J., Wenk, M. R., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc9317 · Cited by 324
Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Chang, C.-H., Lin, C.-H., & Lane, H.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052761 · Cited by 257
Systemic and central nervous system metabolic alterations in Alzheimer’s disease
van der Velpen, V., Teav, T., Gallart-Ayala, H., Mehl, F., Konz, I., Clark, C., Oikonomidi, A., Peyratout, G., Henry, H., Delorenzi, M., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0551-7 · Cited by 253
Metadata
- Authors
- Varma, V. R., Oommen, A. M., Varma, S., Casanova, R., An, Y., Andrews, R. M., O’Brien, R., Pletnikova, O., Troncoso, J. C., Toledo, J., Baillie, R., Arnold, M., Kastenmueller, G., Nho, K., Doraiswamy, P. M., Saykin, A. J., Kaddurah-Daouk, R., Legido-Quigley, C., & Thambisetty, M.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-01-25
- Volume
- 15
- Issue
- 1
- Pages
- e1002482
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2784429314
- Cited by
- 475
- References
- 61
- FWCI
- 33.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.